William Fry has advised Innocoll Holdings plc (NASDAQ: INNL), a specialty pharmaceutical and medical device company with late stage development programmes targeting areas of significant unmet medical need, in respect of its recent US$40.1 million placing. The placing, underwritten by Morgan Stanley and Piper Jaffray, was in respect of 5,725,000 shares at a price to the public of US$7.00 per share.  The underwriters also have an over-allotment option over an additional 858,750 shares, subject to certain closing conditions.

The William Fry team advising on the deal was led by David Carthy, who was assisted by Laura Dunne, Sonya Manzor, David Jones and Rachel Fox.

William Fry’s mandate on the Innocoll's placing maintains its position as a leader in advising on public company transactions including advising: Innocoll Holdings plc on its redomiciliation to Ireland, King Digital Entertainment on its acquisition by Activision Blizzard Entertainment; IAG on its acquisition of Aer Lingus; the Department of Finance in assessing options regarding potential disposal of the State’s holdings in Allied Irish Banks plc (AIB) and Forest Laboratories in relation to its $28 billion merger with Actavis plc.

To speak to William Fry regarding capital markets generally please contact David Carthy or David Fitzgibbon.